| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |
Cell Growth & Differentiation, Vol 6, Issue 1 9-17, Copyright © 1995 by American Association of Cancer Research
ARTICLES |
M Ehinger, E Nilsson, AM Persson, I Olsson and U Gullberg
Department of Medicine, University of Lund, Sweden.
The cDNA of the human wild-type p53 tumor suppressor gene was constitutively overexpressed in the leukemic cell line K562 (which lacks detectable amounts of p53 protein) in order to investigate the consequences for growth and differentiation. Several stable clones were established by transfection of the expression vector pc53SN3. Expression of p53 protein was characterized by biosynthetic labeling and immunoprecipitation with the monoclonal antibodies pAb 1801 (reacting with wild-type and mutant human p53), pAb 240 (reacting with mutant human p53) and pAb 1620 (reacting with wild-type human p53). All clones which were 1801+, 240-, 1620- or 1801+, 240-, 1620+ were defined as "wild-type-like p53-expressing" clones. Our results show that expression of p53 protein is compatible with continuous proliferation of K562 cells. The growth characteristics of wild-type-like p53-expressing clones did not differ from that of control clones. However, the former were more sensitive than p53-negative control clones to growth inhibition by tumor necrosis factor (TNF), a cytokine with a potential role in growth and differentiation of myeloid leukemic cells. In addition, a 2- to 4-fold increase of the amount of hemoglobin, a marker of erythroid differentiation, was observed when wild-type-like p53 protein-expressing clones were incubated with TNF. This suggests that differentiation is the mechanism responsible for the increased TNF sensitivity of these clones. Our results support a role for p53 in mediating growth inhibitory and differentiation inducing signals by TNF.
This article has been cited by other articles:
![]() |
P. G. Fuhrken, P. A. Apostolidis, S. Lindsey, W. M. Miller, and E. T. Papoutsakis Tumor Suppressor Protein p53 Regulates Megakaryocytic Polyploidization and Apoptosis J. Biol. Chem., June 6, 2008; 283(23): 15589 - 15600. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. L. Kathrein, R. Lorenz, A. M. Innes, E. Griffiths, and S. Winandy Ikaros Induces Quiescence and T-Cell Differentiation in a Leukemia Cell Line Mol. Cell. Biol., March 1, 2005; 25(5): 1645 - 1654. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. N. Pennington, J. A. Taylor, G. D. Bren, and C. V. Paya I{kappa}B Kinase-Dependent Chronic Activation of NF-{kappa}B Is Necessary for p21WAF1/Cip1 Inhibition of Differentiation-Induced Apoptosis of Monocytes Mol. Cell. Biol., March 15, 2001; 21(6): 1930 - 1941. [Abstract] [Full Text] |
||||
![]() |
K. Chylicki, M. Ehinger, H. Svedberg, and U. Gullberg Characterization of the Molecular Mechanisms for p53-mediated Differentiation Cell Growth Differ., November 1, 2000; 11(11): 561 - 571. [Abstract] [Full Text] |
||||
![]() |
K. Chylicki, M. Ehinger, H. Svedberg, G. Bergh, I. Olsson, and U. Gullberg p53-mediated Differentiation of the Erythroleukemia Cell Line K562 Cell Growth Differ., June 1, 2000; 11(6): 315 - 324. [Abstract] [Full Text] |
||||
![]() |
G. Darnell and D.R. Richardson The Potential of Iron Chelators of the Pyridoxal Isonicotinoyl Hydrazone Class as Effective Antiproliferative Agents III: The Effect of the Ligands on Molecular Targets Involved in Proliferation Blood, July 15, 1999; 94(2): 781 - 792. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Bergh, M. Ehinger, T. Olofsson, B. Baldetorp, E. Johnsson, H. Brycke, G. Lindgren, I. Olsson, and U. Gullberg Altered Expression of the Retinoblastoma Tumor-Suppressor Gene in Leukemic Cell Lines Inhibits Induction of Differentiation But Not G1-Accumulation Blood, April 15, 1997; 89(8): 2938 - 2950. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |